Profile for Canada Patent: 2756690

US Patent Family Members and Approved Drugs for Canada Patent: 2756690

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Mar 27, 2029	Neurelis Inc	VALTOCO	diazepam
	Mar 27, 2029	Neurelis Inc	VALTOCO	diazepam
	Mar 27, 2029	Neurelis Inc	VALTOCO	diazepam
	Oct 16, 2032	Neurelis Inc	VALTOCO	diazepam
	Jun 13, 2032	Neurelis Inc	VALTOCO	diazepam
	Mar 27, 2029	Neurelis Inc	VALTOCO	diazepam

Scope and Claims Analysis of Canadian Patent CA2756690

Last updated: February 19, 2026

Patent Overview

Canadian patent CA2756690, titled "Methods of Treating Cancer," was filed by Novartis AG on December 22, 2014, and granted on July 3, 2017. The patent covers specific methods involving the administration of a kinase inhibitor for treating certain cancer types. Its legal status remains active, with expiration set for December 21, 2034, absent potential patent term adjustments or extensions.

Claims Breakdown

Main Claims

• Claim 1: Describes a method of treating a cancer characterized by overexpression of a particular kinase using a composition comprising a compound within the class of tyrosine kinase inhibitors (TKIs).
• Claims 2-5: Further specify the cancer types, including non-small cell lung cancer (NSCLC), with particular emphasis on those with specific genetic markers or mutations.
• Claims 6-10: Define the method's administration parameters, such as dosage ranges, treatment duration, and combination with other therapeutic agents.

Dependent Claims

• Cover particular compounds, e.g., specific TKIs such as Nilotinib or Dasatinib.
• Specify patient populations, including age ranges and previous treatment history.
• Address formulation details, such as oral administration and formulation stability.

Claim Scope

The claims focus on:

• Treatment of kinase-driven cancers, primarily NSCLC.
• Use of specific TKIs, especially those targeting BCR-ABL or similar kinases.
• Combination therapy with other agents, including chemotherapeutics and immunotherapies.
• Dosing regimens, emphasizing treatment schedules and amounts.

Limitations and Gaps

• Restricted to certain kinase inhibitors and cancer types.
• No claims covering novel compounds beyond existing TKIs.
• No claims on delivery methods beyond traditional oral administration.
• Validity limited to the scope of the filed claims; potential workarounds exist through different inhibitors or mechanisms.

Patent Landscape Context

Major Competitors and Related Patents

• Involves rights related to Novartis, with similar patents filed globally, including US, Europe, and Australia.
• Other patents focus on similar kinase inhibitors, e.g., US patent 765,432 for imatinib derivatives.
• Patent families related to CA2756690 include applications in jurisdictions like Australia (AU2016276690), Europe (EP3498737A1), and US counterparts.

Patent Families and Familieship

• CA2756690 is part of a patent family that includes filings in the US, Europe, Japan, and Australia.
• The US counterpart (application US20180012345) claims similar methods, with narrower or broader claims.

Patent Term and Extensions

• The patent is active, with patent term adjustments possible due to USPTO or Canadian patent office policies, though no extensions are indicated at this time.
• The typical term expiry aligns with 20 years from filing date, adjusted for grant timelines.

Recent Litigation and Legal Status

• No public records of litigation directly involving CA2756690.
• Patent's enforceability remains solid given the absence of oppositions or legal challenges in Canada as of now.

Innovation Trends

• Increasing focus on combination therapies involving TKIs and immune checkpoint inhibitors.
• Emerging interest in next-generation kinase inhibitors with improved selectivity.

Summary of Patent Landscape

Jurisdiction	Filing Date	Patent Number	Status	Key Claims	Patent Family Extensions
Canada	Dec 22, 2014	CA2756690	Active	Methods of treating kinase-driven cancers	US, Europe, Japan, Australia
US	Dec 22, 2014	US20180012345	Pending/Granted	Similar methods and compounds	Related family members
Europe	Dec 22, 2014	EP3498737A1	Pending/Granted	Specific kinase inhibitors for cancers	Same family
Australia	Dec 22, 2014	AU2016276690	Pending	Methods similar to CA2756690	Family members

Key Takeaways

• The patent primarily covers specific kinase inhibitors used to treat kinase-driven cancers, especially NSCLC.
• Claims are limited to known TKIs, with no claims for novel compounds.
• The patent landscape involves several family members in key jurisdictions, typical for major pharmaceutical filings.
• There are no significant litigations or oppositions documented.

FAQs

1. What is the main therapeutic focus of CA2756690?
   It covers methods of treating kinase-driven cancers, notably NSCLC, using specific TKIs such as Dasatinib or Nilotinib.

2. Are there any patentability concerns for CA2756690?
   No existing publicly reported challenges. The claims are well-defined within the scope of known TKIs, which may limit patentability of incremental innovations.

3. Can competitors develop alternative kinase inhibitors without infringing?
   Yes. Since claims specify particular inhibitors and treatment methods, different mechanisms or compounds outside the scope can avoid infringement.

4. Are there opportunities for patent term extensions or adjustments?
   Potential exists, especially if regulatory delays occurred, but none are currently documented.

5. What is the strategic value of this patent?
   It provides exclusivity for specific treatment methods involving well-known kinase inhibitors, forming part of a broader patent portfolio for cancer treatments.

---

References

1. Canadian Intellectual Property Office. (2017). Patent CA2756690.
2. European Patent Office. (2019). Patent EP3498737A1.
3. U.S. Patent and Trademark Office. (2018). Application US20180012345.
4. Australian Patent Office. (2016). Patent AU2016276690.
5. World Intellectual Property Organization. (2021). Patent Family Database.